Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study

NCT02359175 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2023-06-27

No results posted yet for this study

Summary

Whereas it, in the case of conventional thoracotomy, has been demonstrated that thoracic epidural analgesia is more effective than systemic opioids in terms of pain relief and preservation of postoperative pulmonary function, the efficacy of epidural analgesia in video-assisted thoracic surgical (VATS) procedures, has not been sufficiently studied, but a beneficial effect might very well be present.

On the other hand, the risks associated with placement of a thoracic epidural catheter are well known and if similar pain relief can be achieved without it with no or only insignificant alternative side effects, this would be preferable.

The literature regarding the usefulness of epidural analgesia for reducing pain in Video-Assisted Thoracic Surgery is, at best, scarce with two small studies showing some effect and two showing no difference, none of the studies being blinded randomized controlled trials of adequate size.

The SEAVATS Study will try to answer this question.

Conditions

  • Lung Neoplasms
  • Pain
  • Immune Suppression

Interventions

DRUG

Bupivacaine in epidural catheter

Bupivacain to be given in epidural catheter

DRUG

Fentanyl in epidural catheter

Fentanyl to be given in epidural catheter

DRUG

Placebo (for Bupivacain and Fentanyl i epidural catheter)

Saline to be given in epidural catheter

DRUG

Oral Paracetamol

Paracetamol to be given orally

DRUG

Oral NSAID

NSAID to be given orally

DRUG

Oral opioids

Opioids to be given orally

DRUG

Placebo (for oral opioids)

Placebo tablets to be given instead of oral opioids

Sponsors & Collaborators

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Jimmy H Holm, MD · Department of Anaesthesia and Intensive Care - Odense University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2019-01-24
Completion
2023-03-22

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02359175 on ClinicalTrials.gov